@ARTICLE{
author={Weichenthal Michael,...,Kandolf Lidija O,...,(broj koautora 22)},
year={2024},
title={Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe},
journal={CANCERS},
volume={16},
number={21},
pages={-},
document_type={Article},
} 

@ARTICLE{
author={Asher Nethanel,Mohr Peter,Ellebaek Eva,Bender Marc,Mangana Joanna,Kandolf Lidija O,Gavrilova Iva,Ascierto Paolo Antonio,Gogas Helen,Rutkowski Piotr,Schadendorf Dirk,Bastholt Lars,Weichenthal Michael},
year={2024},
title={Length of treatment after partial or complete remission in immunotherapy for metastatic melanoma: An EUMelaReg real world study},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={42},
number={16},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Weichenthal Michael,...,Kandolf-Sekulovic Lidija O,...,(broj koautora 20)},
year={2022},
title={Outcome of PD-1 inhibitor therapy of advanced melanoma patients according to demographic factors in a real-world setting across Europe},
journal={ANNALS OF ONCOLOGY},
volume={33},
number={7},
pages={S931-S931},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Weichenthal Michael,...,Kandolf-Sekulovic Lidija O,...,(broj koautora 20)},
year={2022},
title={EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600-mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={40},
number={16},
pages={-},
document_type={Meeting Abstract},
}